Advancements in Antibody-Based Immunotherapy and Cancer Vaccines for Hepatocellular Carcinoma

5,235
Total downloads
19k
Total views and downloads

Articles

ORIGINAL RESEARCH

Published on 17 Jul 2025

Postoperative hepatitis B virus reactivation and its impact on survival in HBV-related hepatocellular carcinoma patients undergoing conversion therapy with interventional therapy combined with tyrosine kinase inhibitors and immune checkpoint inhibitors

Shaowei Xu
Qingqing Pang
Meng Wei
Danxi Liu
Du Yuan
Tao Bai
Xiaobo Wang
Zhihong Tang
Feixiang Wu

doi 10.3389/fcimb.2025.1598193

729 views

REVIEW

Published on 20 Jun 2025

Antibody treatment of hepatocellular carcinoma: a review of current and emerging approaches

Sherif A. El-Kafrawy
Mostafa S. Elkafrawy
Esam I. Azhar
Anwaar Saeed
Ashraf A. Tabll

doi 10.3389/fimmu.2025.1533874

1,759 views

ORIGINAL RESEARCH

Published on 05 Jun 2025

Dissecting the multi-omics landscape of TEAD1 in hepatocellular carcinoma: cycle regulation and metastatic potential

Ruiping Huai
Canquan Mao
Lili Xiong

doi 10.3389/fimmu.2025.1567969

1,205 views

ORIGINAL RESEARCH

Published on 08 May 2025

A conceptual exploration on the synergistic anti-tumor effects of high-order combination of OHSV2-DSTEFAP5/CD3, CAR-T cells, and immunotoxins in hepatocellular carcinoma

Shuang Dong
Xin Chen
Xiaoyu Li
Yang Wang
Qing Huang
Yuanxiang Li
Jing Jin
Xianmin Zhu
Yi Zhong
6 more
Sheng Hu

doi 10.3389/fimmu.2025.1509087

1,893 views

ORIGINAL RESEARCH

Published on 10 Dec 2024

Prognostic significance of combined PD-L1 expression in malignant and infiltrating cells in hepatocellular carcinoma treated with atezolizumab and bevacizumab

Jaejun Lee
Jae-Sung Yoo
Ji Hoon Kim
Dong Yeup Lee
Keungmo Yang
Bohyun Kim
Joon-Il Choi
Jeong Won Jang
Jong Young Choi
2 more
Pil Soo Sung

doi 10.3389/fimmu.2024.1506355

1,932 views
1 citation

ORIGINAL RESEARCH

Published on 23 Oct 2024

Comparing PD-L1 with PD-1 antibodies combined with lenvatinib and hepatic arterial infusion chemotherapy for unresectable hepatocellular carcinoma

Shaohua Li
Jie Mei
Rongce Zhao
Jing Zhou
Qiaoxuan Wang
Lianghe Lu
Jibin Li
Lie Zheng
Wei Wei
Rongping Guo

doi 10.3389/fimmu.2024.1491857

2,055 views
2 citations

SYSTEMATIC REVIEW

Published on 02 Aug 2024

Immune-targeted therapy with transarterial chemo(embolization) for unresectable HCC: a systematic review and meta-analysis

Huipeng Fang
Qiao Ke
Shiji Wu
Qiang Tu
Lei Wang

doi 10.3389/fimmu.2024.1421520

2,501 views
2 citations

ORIGINAL RESEARCH

Published on 26 Jul 2024

TACE plus lenvatinib and tislelizumab for intermediate-stage hepatocellular carcinoma beyond up-to-11 criteria: a multicenter cohort study

Song Chen
Tang Shuangyan
Feng Shi
Hongjie Cai
Zhiqiang Wu
Liguang Wang
Ping Ma
Yuanmin Zhou
Qicong Mai
4 more
Wenbo Guo

doi 10.3389/fimmu.2024.1430571

2,335 views
4 citations

Share on

Frontiers in Immunology

Cancer Immunity and Immunotherapy

Participating Journals

Frontiers in Oncology
- Cancer Immunity and Immunotherapy
- 3.3 impact factor
- 6.9 citescore

Impact

19kTopic views
13kArticle views
5,235Article downloads

View impact

Articles

Postoperative hepatitis B virus reactivation and its impact on survival in HBV-related hepatocellular carcinoma patients undergoing conversion therapy with interventional therapy combined with tyrosine kinase inhibitors and immune checkpoint inhibitors

Antibody treatment of hepatocellular carcinoma: a review of current and emerging approaches

Dissecting the multi-omics landscape of TEAD1 in hepatocellular carcinoma: cycle regulation and metastatic potential

A conceptual exploration on the synergistic anti-tumor effects of high-order combination of OHSV2-DSTEFAP5/CD3, CAR-T cells, and immunotoxins in hepatocellular carcinoma

Prognostic significance of combined PD-L1 expression in malignant and infiltrating cells in hepatocellular carcinoma treated with atezolizumab and bevacizumab

Comparing PD-L1 with PD-1 antibodies combined with lenvatinib and hepatic arterial infusion chemotherapy for unresectable hepatocellular carcinoma

Immune-targeted therapy with transarterial chemo(embolization) for unresectable HCC: a systematic review and meta-analysis

TACE plus lenvatinib and tislelizumab for intermediate-stage hepatocellular carcinoma beyond up-to-11 criteria: a multicenter cohort study

Frontiers in Immunology

Cancer Immunity and Immunotherapy

Participating Journals

Frontiers in Oncology

Cancer Immunity and Immunotherapy